BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review

Nieto, Rodrigo; Carrasco, Andrea; Corral, Sebastián; Castillo, Rodrigo; Gaspar, Pablo A.; Bustamante, M. Leonor; Silva, Hernán

doi:10.3389/fpsyt.2021.662407

Cited by 48 publications

(35 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on our findings, it may be assumed that the associations between PA and general psychopathology (weighted r = 0.45) may be larger than those observed for PA and positive/negative symptoms (weighted r s of 0.17 to 0.21). This is in line with research linking cognitive functioning in psychosis and BDNF, the neurotropic factor affected by PA. Low BDNF is typical among people with psychotic diseases [ 12 ]. BDNF levels may be increased through regular PA [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…BDNF levels may be increased through regular PA [ 10 ]. Recent research emphasizes that the associations between BDNF levels and schizophrenia symptoms, but mostly regarding symptoms, are related to poor cognitive functioning (e.g., working memory, attention, processing speed, motor function, and executive function; for review see [ 12 ]). Symptoms related to poor cognitive functioning are best captured by the general psychopathology symptoms of psychosis.…”

Section: Discussionmentioning

confidence: 99%

“…Importantly, low levels of BDNF are associated with higher levels of symptoms of schizophrenia [ 11 ]. The associations between BDNF and psychosis symptoms may be particularly salient in the area of cognitive functioning (e.g., processing speed, memory, and executive function; for a review see [ 12 ]). In addition to physiological links between PA and symptoms of psychosis, psychosocial factors may mediate the BDNF—psychosis symptoms association.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Physical Activity, Positive and Negative Symptoms of Psychosis, and General Psychopathology among People with Psychotic Disorders: A Meta-Analysis

Swora

Boberska

Kuliś

et al. 2022

JCM

View full text Add to dashboard Cite

Objective: Existing reviews provided evidence for the associations between higher physical activity (PA) and lower negative symptoms of psychosis among people with schizophrenia. This meta-analysis goes beyond existing syntheses and investigates associations between PA, positive and negative symptoms of psychosis, as well as symptoms of general psychopathology (referring mostly to cognitive functioning) among people with schizophrenia, but also other psychotic disorders. The moderating roles of the type of diagnosis and the type of exercise intervention were explored. Methods: The study was registered with PROSPERO (CRD42018118236). Six electronic databases were searched; n = 27 experimental and observational studies were included, and psychotic symptoms-related data were recorded in one direction (higher values indicate better mental health and lower symptomatology). Results: Higher levels of PA (or participating in PA interventions) were associated with better mental health, that is, lower levels of positive symptoms (all studies: r = 0.170; experimental studies: SMD = 0.677), negative symptoms (all studies: r = 0.214; experimental studies: SMD = 0.838), and general psychopathology (all studies: r = 0.451; experimental studies: SMD = 1.511). The type of diagnosis (schizophrenia vs. other psychotic disorders) did not moderate these associations. Conclusions: We found a consistent pattern of associations between higher levels of PA and lower positive, negative, and general psychopathology symptoms in people with schizophrenia and those with other psychotic disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Physical Activity, Positive and Negative Symptoms of Psychosis, and General Psychopathology among People with Psychotic Disorders: A Meta-Analysis

Swora

Boberska

Kuliś

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Considering the limited number of avialable studies, no arbitrary criteria were applied to restrict the number of studies to discuss. Candidate gene studies mostly focused on the BDNF gene, based on different lines of evidence supporting its potential role in the pathogenesis of severe mental disorders [79][80][81]. D'Addario and colleagues measured the degree of DNA methylation at the BDNF promoter region, as well as mRNA levels of the gene, in peripheral blood mononuclear cells (PBMC) from 94 patients with BD and 52 controls matched for age, gender and origin.…”

Section: Candidate Gene Studiesmentioning

confidence: 99%

Genetic and Epigenetic Markers of Lithium Response

Pisanu

Meloni

Severino

et al. 2022

IJMS

View full text Add to dashboard Cite

The mood stabilizer lithium represents a cornerstone in the long term treatment of bipolar disorder (BD), although with substantial interindividual variability in clinical response. This variability appears to be modulated by genetics, which has been significantly investigated in the last two decades with some promising findings. In addition, recently, the interest in the role of epigenetics has grown significantly, since the exploration of these mechanisms might allow the elucidation of the gene–environment interactions and explanation of missing heritability. In this article, we provide an overview of the most relevant findings regarding the pharmacogenomics and pharmacoepigenomics of lithium response in BD. We describe the most replicated findings among candidate gene studies, results from genome-wide association studies (GWAS) as well as post-GWAS approaches supporting an association between high genetic load for schizophrenia, major depressive disorder or attention deficit/hyperactivity disorder and poor lithium response. Next, we describe results from studies investigating epigenetic mechanisms, such as changes in methylation or noncoding RNA levels, which play a relevant role as regulators of gene expression. Finally, we discuss challenges related to the search for the molecular determinants of lithium response and potential future research directions to pave the path towards a biomarker guided approach in lithium treatment.

show abstract

“…BDNF rs6265 (Val66Met) is one of the main candidate genes in major depression [ 28 ] and in schizophrenia [ 29 ], and it has been implicated in cognitive deficits exhibited by the patients. Likewise, the existence of BDNF polymorphisms has been confirmed in DD patients with schizophrenia [ 30 ] and with altered cognitive performance.…”

Section: Introductionmentioning

confidence: 99%

Protocol for Characterization of Addiction and Dual Disorders: Effectiveness of Coadjuvant Chronotherapy in Patients with Partial Response

Adán

Navarro

2022

JCM

View full text Add to dashboard Cite

This protocol aims to characterize patients with dual disorders (DD; comorbid major depression and schizophrenia) compared with patients with only a diagnosis of substance use disorder (SUD) and those with only a diagnosis of severe mental illness (SMI; major depression and schizophrenia), evaluating clinical and personality characteristics, circadian rhythmic functioning, genetic polymorphism and neuropsychological performance in order to obtain a clinical endophenotype of differential vulnerability for these diagnostic entities. Patients will be divided into three groups: DD (45 men with comorbid schizophrenia, 45 men and 30 women with major depression), SUD (n = 90, with a minimum of 30 women) and SMI males (45 with schizophrenia, 45 with major depression). All patients will be under treatment, with at least three months of SUD abstinence and/or with SMI in remission or with stabilized symptoms. Outpatients of both sexes with insufficient restoration of circadian rhythmicity with SUD (n = 30) and dual depression (n = 30) will be asked to participate in a second two-month study, being alternately assigned to the condition of the chronobiological adjuvant approach to the treatment of regular hour habits and exposure to light or to the usual treatment (control). The effect of the intervention and patient compliance will be monitored with a Kronowise KW6® ambulatory device during the first two weeks of treatment and again at weeks 4 and 8 weeks. After completing the evaluation, follow-up of the clinical evolution will be carried out at 3, 6 and 12 months. This project will allow us to analyze the functional impact of DD comorbidity and to develop the first study of chronobiological therapy in the treatment of SUD and dual depression, with results transferable to the clinical setting with cost-effective recommendations for a personalized approach.

show abstract

BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review

Cited by 48 publications

References 72 publications

Physical Activity, Positive and Negative Symptoms of Psychosis, and General Psychopathology among People with Psychotic Disorders: A Meta-Analysis

Physical Activity, Positive and Negative Symptoms of Psychosis, and General Psychopathology among People with Psychotic Disorders: A Meta-Analysis

Genetic and Epigenetic Markers of Lithium Response

Protocol for Characterization of Addiction and Dual Disorders: Effectiveness of Coadjuvant Chronotherapy in Patients with Partial Response

Contact Info

Product

Resources

About